Key Highlights
- Loss was USD 0.75 per share against an estimated USD 0.73 loss, and Revenue of USD 0.395 million missed.
- Net loss for the quarter was USD 41.2 million, compared with USD 33.7 million in the same period last year.
- Cash, cash equivalents and short-term investments were USD 207.4 million, down from USD 341.5 million at year end.
- The company's focus is verekitug in severe asthma, chronic rhinosinusitis with nasal polyps and COPD.
Upstream Bio (NASDAQ:UPB), a clinical-stage biotechnology company, reported a third quarter 2026 loss of USD 0.75 per share, wider than the USD 0.73 estimated loss. Revenue of USD 0.395 million fell short of the USD 0.549 million estimate. The revenue consisted of collaboration revenue, which was USD 0.4 million for the quarter against USD 0.7 million a year earlier, and USD 2.2 million for each of the nine-month periods in 2026 and 2025.
Net loss for the quarter was USD 41.2 million, compared with USD 33.7 million in the third quarter of 2025. For the nine months, net loss was USD 121.5 million, against USD 101.0 million a year earlier. The accumulated Deficit stood at USD 455.7 million.
Cash Position and Funding History
Cash, cash equivalents and short-term investments totaled USD 207.4 million at September 30. The Balance Sheet shows cash and equivalents of USD 47.4 million and short-term investments of USD 159.9 million, compared with USD 101.6 million and USD 239.9 million at December 31. Together, those year-end figures add up to roughly USD 341.5 million, so the balance fell by about USD 134 million in nine months.
Since inception the company has received an aggregate of USD 670.9 million from financing transactions. That includes gross proceeds of USD 400.0 million from redeemable convertible preferred stock, USD 268.8 million in net proceeds from its initial public offering and USD 2.1 million in net proceeds from common stock sold under its at-the-market program.
The at-the-market program, set up in March 2026 through Leerink Partners for up to USD 150.0 million, has been used lightly. The company has sold 239,797 shares under it in total, and made no sales in the third quarter. The filing notes the sales agent is entitled to a commission of up to 3.0% of gross proceeds.
Verekitug Development Focus
The company's focus is verekitug, with development centered on severe asthma, chronic rhinosinusitis with nasal polyps and COPD. The filing refers to a Phase 3 clinical trial of verekitug in severe asthma in connection with performance-based Equity awards, whose vesting depends on achievement of a specified milestone in that trial.
The filing notes that failure to pay royalties owed to Regeneron could affect the company's rights to verekitug, and it lists clinical trial delays and competition for patients among its risk factors. It also notes that the company may pursue additional indications over the longer term.
The filing states that, until the company can generate significant product revenue, if ever, it plans to fund operations through equity offerings, debt financings and collaborations.
Figures That Frame the Next Quarter
Quarterly net loss relative to the USD 207.4 million cash balance, further use of the at-the-market program, and progress on the Phase 3 asthma trial are the items to follow. Collaboration revenue is small and variable, so the loss is driven by research spending.






Please wait processing your request...